NasdaqGM:TRHC

Stock Analysis Report

Executive Summary

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the field of medication safety in the United States.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Share Price & News

How has Tabula Rasa HealthCare's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-6.2%

TRHC

-0.1%

US Healthcare Services

1.0%

US Market


1 Year Return

-32.7%

TRHC

15.8%

US Healthcare Services

6.7%

US Market

Return vs Industry: TRHC underperformed the US Healthcare Services industry which returned 15.8% over the past year.

Return vs Market: TRHC underperformed the US Market which returned 6.7% over the past year.


Share holder returns

TRHCIndustryMarket
7 Day-6.2%-0.1%1.0%
30 Day-7.9%-0.9%-1.8%
90 Day-3.6%-7.5%-1.8%
1 Year-32.7%-32.7%16.0%15.8%9.1%6.7%
3 Year269.4%269.4%57.5%57.0%46.1%36.6%
5 Yearn/a52.5%51.4%66.9%48.6%

Price Volatility Vs. Market

How volatile is Tabula Rasa HealthCare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tabula Rasa HealthCare undervalued based on future cash flows and its price relative to the stock market?

32%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Undervalued: TRHC ($51.38) is trading below our estimate of fair value ($75.46)

Significantly Undervalued: TRHC is trading below fair value, but not by a significant amount.


Price Based on Earnings

PE vs Industry: TRHC is unprofitable, so we can't compare its PE Ratio to the Healthcare Services industry average.

PE vs Market: TRHC is unprofitable, so we can't compare its PE Ratio to the US market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate TRHC's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: TRHC is overvalued based on its PB Ratio (5.8x) compared to the US Healthcare Services industry average (3.5x).


Next Steps

Future Growth

How is Tabula Rasa HealthCare expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

36.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: TRHC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TRHC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TRHC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TRHC's revenue (17.2% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: TRHC's revenue (17.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if TRHC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Tabula Rasa HealthCare performed over the past 5 years?

-34.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: TRHC is unprofitable, and losses have increased over the past 5 years at a rate of -34.5% per year.

Accelerating Growth: Unable to compare TRHC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TRHC is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (3.3%).


Return on Equity

High ROE: TRHC has a negative Return on Equity (-9.6%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: TRHC is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: TRHC is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Tabula Rasa HealthCare's financial position?


Financial Position Analysis

Short Term Liabilities: TRHC's short term assets ($103.0M) exceeds its short term liabilities ($52.4M)

Long Term Liabilities: TRHC's short term assets (103.0M) do not cover its long term liabilities (271.4M)


Debt to Equity History and Analysis

Debt Level: TRHC's debt to equity ratio (119.7%) is considered high

Reducing Debt: TRHC's debt to equity ratio has reduced from 3096.6% to 119.7% over the past 5 years.


Balance Sheet

Inventory Level: TRHC has a low level of unsold assets or inventory.

Debt Coverage by Assets: TRHC's debt is not covered by short term assets (assets are 0.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TRHC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TRHC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Tabula Rasa HealthCare's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate TRHC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate TRHC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if TRHC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TRHC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TRHC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Tabula Rasa HealthCare's salary, the management and board of directors tenure and is there insider trading?

5.0yrs

Average management tenure


CEO

Calvin Knowlton (69yo)

5.3yrs

Tenure

US$3,540,088

Compensation

Dr. Calvin H. Knowlton, BSc Pharm, MDiv, Ph.D., is a Co-Founder of Tabula Rasa Healthcare, Inc. and has been its Chairman and Chief Executive Officer since June 2014. Dr. Knowlton founded CareKinesis, Inc. ...


CEO Compensation Analysis

Compensation vs. Market: Calvin's total compensation ($USD3.54M) is about average for companies of similar size in the US market ($USD2.71M).

Compensation vs Earnings: Calvin's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

5.0yrs

Average Tenure

53yo

Average Age

Experienced Management: TRHC's management team is seasoned and experienced (5 years average tenure).


Board Age and Tenure

1.7yrs

Average Tenure

62yo

Average Age

Experienced Board: TRHC's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: TRHC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$438,29723 Aug 19
A. Tunstall
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares6,742
Max PriceUS$65.01
SellUS$186,65816 Aug 19
Samira Beckwith
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares3,044
Max PriceUS$61.32
SellUS$174,36104 Jan 19
Brian Adams
EntityIndividual
Role
Chief Financial Officer
CFO & Secretary
Shares3,035
Max PriceUS$57.45
SellUS$59,35804 Jan 19
Andrea Speers
EntityIndividual
Role
Chief Accounting Officer
Corporate Controller & Chief Accounting Officer
Shares1,022
Max PriceUS$58.08
SellUS$131,29214 Dec 18
Samira Beckwith
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,733
Max PriceUS$75.76
BuyUS$487,52914 Nov 18
Calvin Knowlton
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares7,500
Max PriceUS$65.77

Ownership Breakdown


Management Team

  • Calvin Knowlton (69yo)

    Co-Founder

    • Tenure: 5.3yrs
    • Compensation: US$3.54m
  • Joseph Filippoli (53yo)

    Chief Information Officer

    • Tenure: 5.3yrs
  • Orsula Knowlton (50yo)

    Co-Founder

    • Tenure: 5.8yrs
    • Compensation: US$2.74m
  • Tom Wilson

    Chief Technology Innovation Officer & EVP of eHealth Services

    • Tenure: 0.8yrs
  • Michael Greenhalgh

    Chief Operating Officer

    • Tenure: 5.3yrs
  • Phillip Heath (53yo)

    Chief Administrative Officer

    • Tenure: 4.7yrs
  • Brian Adams (37yo)

    CFO & Secretary

    • Tenure: 5.3yrs
    • Compensation: US$1.66m
  • Jacques Turgeon (59yo)

    Chief Scientific Officer

    • Tenure: 4.1yrs
  • Kevin Dill

    General Counsel

    • Tenure: 3yrs
  • Andrea Speers (37yo)

    Corporate Controller & Chief Accounting Officer

    • Tenure: 1.7yrs

Board Members

  • Calvin Knowlton (69yo)

    Co-Founder

    • Tenure: 5.3yrs
    • Compensation: US$3.54m
  • A. Tunstall (75yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$164.50k
  • Jan Berger (61yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$523.86k
  • Dennis Helling (70yo)

    Independent Director

    • Tenure: 2.6yrs
    • Compensation: US$146.00k
  • Orsula Knowlton (50yo)

    Co-Founder

    • Tenure: 5.8yrs
    • Compensation: US$2.74m
  • Michael Purcell (62yo)

    Director

    • Tenure: 1.3yrs
    • Compensation: US$506.36k
  • Samira Beckwith (66yo)

    Independent Director

    • Tenure: 2.2yrs
    • Compensation: US$141.25k
  • Kathrine O'brien (56yo)

    Independent Director

    • Tenure: 0.9yrs
    • Compensation: US$570.59k
  • Pamela Schweitzer (60yo)

    Independent Director

    • Tenure: 0.6yrs

Company Information

Tabula Rasa HealthCare, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tabula Rasa HealthCare, Inc.
  • Ticker: TRHC
  • Exchange: NasdaqGM
  • Founded: 2009
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: US$1.061b
  • Shares outstanding: 20.64m
  • Website: https://www.tabularasahealthcare.com

Number of Employees


Location

  • Tabula Rasa HealthCare, Inc.
  • 228 Strawbridge Drive
  • Suite 100
  • Moorestown
  • New Jersey
  • 8057
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TRHCNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDSep 2016
43TDB (Deutsche Boerse AG)YesCommon StockDEEURSep 2016

Biography

Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the field of medication safety in the United States. The company’s proprietary Medication Risk Mitigation Matrix delivers a multi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 03:20
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)